Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages e38-e41 , August 2010

Subgroup analyses of etanercept in pediatric patients with psoriasis

Presented in poster form at the 2009 Summer Academy American Academy of Dermatology Congress (#P2004). This study is registered with clinicaltrials.gov with the identifier NCT00078819.

  • Amy S. Paller, MD

      Affiliations

    • Children's Memorial Hospital and Northwestern University Medical School, Chicago, Illinois
    • Corresponding Author InformationCorrespondence to: Amy S. Paller, MD, Department of Dermatology, Children's Memorial Hospital and Northwestern University Medical School, 676 N St Clair St, Ste 1600, Chicago, IL 60611-2941
    • ,
  • Lawrence F. Eichenfield, MD

      Affiliations

    • Rady Children's Hospital and the University of California San Diego, San Diego, California
    • ,
  • Richard G. Langley, MD

      Affiliations

    • Dalhousie Medical School, Halifax, Nova Scotia, Canada
    • ,
  • Craig L. Leonardi, MD

      Affiliations

    • Saint Louis University School of Medicine, Saint Louis, Missouri
    • ,
  • Elaine C. Siegfried, MD

      Affiliations

    • Cardinal Glennon Children's Hospital and Saint Louis University, Saint Louis, Missouri
    • ,
  • Kara Creamer, MS

      Affiliations

    • Amgen, Thousand Oaks, California
    • ,
  • Gregory Kricorian, MD

      Affiliations

    • Amgen, Thousand Oaks, California

References 

  1. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–251
  2. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–186
  3. Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 suppl. 2):S101–S111

 Supported by Immunex, a wholly owned subsidiary of Amgen, and by Wyeth Pharmaceuticals. Financial support for the preparation of the manuscript was provided by Amgen.

 Dr Paller is an investigator for Amgen and serves as a consultant for and receives honoraria from Centocor and Abbott Laboratories. Dr Eichenfield is an investigator and past consultant for Amgen and is a consultant and receives an honorarium from Centocor. Dr Langley is on the scientific advisory boards of Amgen, Wyeth, Centocor, Serono, and Abbott Laboratories; serves on the speakers' bureaus for Amgen, Wyeth, Abbott Laboratories, Serono, and Biogen Idec; receives research support from Amgen, Wyeth, Centocor, Serono, and Abbott Laboratories; and receives other grant support from Abbott Laboratories, Amgen, Biogen Idec, Boehringer Ingelheim, Centocor, Celgene, Isotechnika, and Serono. Dr Leonardi is a consultant for Amgen, Abbott, Centocor, and Genentech; serves as an investigator for Amgen, Abbott, Allergan, Altana, Alza, Astellas, Celgene, Centocor, Genentech, Bristol Myers, Eli Lilly, Galderma, Genyme, Pfizer, Incyte, CombinatoRx, 3M Pharmaceuticals, Perrigo Israel Pharmaceutical, ScheringPlough, RTL, Novartis, Vitac, and Wyeth; and serves on the speakers' bureau for Amgen, Abbott, Centocor, Genentech, and Warner Chilcott. Dr Siegfried is a consultant and investigator for Amgen, an investigator for Leo, and a consultant for Abbott Laboratories. Ms Creamer and Dr Kricorian are Amgen employees and receive stock or stock options from Amgen.

PII: S0190-9622(09)01366-8

doi: 10.1016/j.jaad.2009.11.001

Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages e38-e41 , August 2010

Article Tools